Cardiol Therapeutics Inc. (Class A) (CRDL) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cardiol Therapeutics Inc. (Class A) (NASDAQ: CRDL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.11 (-5.13% 1D, market cap $141.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CRDL ranks #272 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, CRDL leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
For Cardiol Therapeutics Inc. (Class A) (CRDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.0M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
While CRDL currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.62) and Max Pain ($1.17) forces dealer call-delta covering toward $2.46.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cardiol Therapeutics Inc. (Class A) (CRDL) dropped -5.13% to $1.11, trading at 16% of its 52-week range ($0.88 – $2.34). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
ABN Newswire report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRDL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRDL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardiol Therapeutics Inc. (Class A) (CRDL) ranks #272 by composite RQD confidence (52/100, grade D+) and #617 by equity capitalization ($141.2M). Within this direct 5-issuer industry benchmark cohort, CRDL leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRDL
ACTIVE
Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | -5.13% | $141.2M | Benchmark Subject |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -7.60% | $138.8M | /chrs-vs-crdl → |
| CMPX Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | +4.01% | $136.2M | /cmpx-vs-crdl → |
| TARA Protara Therapeutics Inc. | D- | 43/100 | — | — | -34.7% | -1.59% | $148.9M | /tara-vs-crdl → |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | +1.42% | $132.4M | /moln-vs-crdl → |
Cardiol Therapeutics Inc. (Class A) (CRDL) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $141.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Cardiol Therapeutics Inc. (Class A) (NASDAQ: CRDL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.11 (-5.13% 1D, market cap $141.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CRDL ranks #272 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDL carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, CRDL leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
For Cardiol Therapeutics Inc. (Class A) (CRDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #272 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
CRDL last traded at $1.11 (-5.13% on volume of 711,711 shares), positioning the stock -31.48% below its 50-day simple moving average ($1.62) and -14.62% below its 200-day simple moving average ($1.30). Across its 52-week range of $0.88 to $2.34, CRDL sits at the 15.8% percentile with a 14-day RSI of 29.6 (OVERSOLD (<32)) and an implied next-earnings move of ±11.9% ($1.00 to $1.24).
Why CRDL Stock dropped -5.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CRDL carries an RQD Score of 52 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:
For a prospective investor evaluating the stock today, the rating points to weak operating fundamentals (zero margins, zero ROIC, zero FCF yield) with only the balance-sheet pillar offering partial support. Upside would depend on a catalyst that the sources do not quantify; the rating itself frames the stock as a trim candidate rather than an accumulation candidate. This is an analytical summary, not personalized advice.
Per the recent news and catalysts feed, six items were published on the coverage window, all tagged to CRDL and all rated YELLOW light with a MARKET WIRE impact label:
Risk watch items per the feed: Phase III trial progress, cash burn, and short-interest positioning. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals (see below).
Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," with an empty set of butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). Because no upstream or downstream dependencies are mapped, no second-order bottlenecks or sector-correlation effects can be stated from the source data. Investors should note that the absence of mapped links is itself a data gap, not evidence of independence.
Real-time company headlines, analyst actions, and sector developments for Cardiol Therapeutics Inc. (Class A) (CRDL) • Click "Debate This Headline" to argue it in the Roar Pit below
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
ABN Newswire report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Cardiol Therapeutics Inc. (Class A) (CRDL) market action, institutional positioning, and fundamental catalysts.
Welcome to the CRDL (Cardiol Therapeutics Inc. (Class A)) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CRDL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cardiol Therapeutics Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CRDL, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.11 (52-wk range $0.88 - $2.34), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).